Key result
Mononegavirales polymerase inhibitors highlight conserved targets for broad-spectrum antiviral drug development.
Why the study?
Recent cryo-EM discoveries have elucidated the structures of Mononegavirales RNA polymerases and their interactions with small-molecule inhibitors, providing insights for antiviral design.
Answers are grounded in this paper and cite their sources.
Structural insights into Mononegavirales RNA polymerases and their interaction with small-molecule inhibitors provide a foundation for developing new broad-spectrum antivirals.
The order Mononegavirale s includes several non‐segmented negative‐sense RNA viruses that are significant human pathogens, whose transcription and replication depend on multifunctional RNA‐dependent RNA polymerase (L protein). Recent discoveries in cryo‐electron microscopy (cryo‐EM) have elucidated the structures of these polymerases and their interactions with small‐molecule inhibitors, providing possible insights for antiviral design. This review summarizes current developments and discoveries in small‐molecule inhibition of Mononegavirales polymerases, exploring nucleoside/nucleotide inhibitors that target the catalytic site and non‐nucleoside inhibitors that engage allosteric pockets within the L protein. By combining biochemical and structural findings, these studies reveal conserved druggable pockets, providing opportunities for the development of broad‐spectrum antivirals drugs against Mononegavirales pathogens.
No takes yet. Share an insight, caveat, or question.
Cao et al. (2026) conducted a review in Mononegavirales viral infections. Small-molecule RNA polymerase inhibitors (nucleoside and non-nucleoside inhibitors) was evaluated. Small-molecule inhibitors targeting the catalytic sites and allosteric pockets of Mononegavirales RNA polymerases reveal conserved druggable targets for broad-spectrum antiviral drug development.
Synapse has enriched 10 related papers. Consider them for comparative context: